Jimmitti Teysir, MD
Enriched profileBreast Medical Oncologist · Memorial Sloan Kettering Cancer Center
Jimmitti Teysir is Breast Medical Oncologist at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 16 publications with 608 citations (h-index 6).
Data verified 13 Nov 2026
Overview
Updated 17 Nov 2026
Jimmitti Teysir, MD, is Breast Medical Oncologist at Memorial Sloan Kettering Cancer Center. The public record shows 16 publications with 608 citations (h-index 6), centered on Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Advanced Breast Cancer Therapies. It also documents industry payments reported by 2 companies.
- Top research focus: Cancer Genomics and Diagnostics
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 17 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. 2 in PubMed. Counts exclude supporting files.
Citations across these publications.
H-index from these publications. i10-index 5.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
No public contact details on file. This person's NPPES record doesn't include a practice address or telephone number. Why? →
Clinical trials
We didn't find any investigator roles for this person on ClinicalTrials.gov. Why? →
Industry payments
Updated 13 Nov 2026
2 companies reported payments to CMS in program years 2025–2025. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20251 payment
- Genentech, Inc.Program year20251 payment
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
61.3%Gabapentinoids61.3%Gabapentin100%Part D<11 patientsCardiovascular
38.7%Statin38.7%Atorvastatin Calcium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 13 Nov 2026
4 congress contributions (2025–2026) across ASCO per OpenAlex. The most recent:
- Characterization of inavolisib-associated hyperglycemia in metastatic hormone receptor–positive (HR+) breast cancer.
ASCO Annual Meeting
ASCO2026Co-author - Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC).
ASCO Annual Meeting
ASCO2025Co-author - Treatment patterns in HR+/HER2- metastatic breast cancer (MBC) with co-occurring PIK3CA and ESR1 mutations.
ASCO Annual Meeting
ASCO2025Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Characterization of inavolisib-associated hyperglycemia in metastatic hormone receptor–positive (HR+) breast cancer.
Journal of Clinical Oncology
2026 - After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor–Positive Metastatic Breast Cancer
American Society of Clinical Oncology Educational Book
2025 - Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC).
Journal of Clinical Oncology
2025
Most-cited works
by citation count (OpenAlex)- 01Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNAArticle456 citations2018
- 02
- 03Disparities in osteoporosis care among postmenopausal women in the United StatesReview40 citations2021
- 04
- 05Racial disparities in surveillance mammography among older breast cancer survivorsArticle15 citations2019
Network
Updated 13 Nov 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 13 Nov 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jimmitti-teysir-md
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
mskcc.org/cancer-care/doctors/jimmitti-teysir
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Icahn School of Medicine at Mount Sinai
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - BA
Yale University
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- T32 Hematology–Oncology Research Training Grant Fellow
National Cancer Institute (NCI)/Memorial Sloan Kettering Cancer Center
2025verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →womenleadersinoncology.com ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Marc Ladanyi, MD
Memorial Sloan Kettering Cancer Center
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Murray Brennan, MD
Memorial Sloan Kettering Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Norman Wolmark, MD
University of Pittsburgh
Hope Rugo, MD
City of Hope